Medoncare Pharmaceutical

Medoncare Pharmaceutical is a specialized biopharmaceutical company headquartered in Changsha, China, focusing on the development of treatments for urological and oncological conditions. The company is particularly recognized for its expertise in modernizing Traditional Chinese Medicine (TCM) through rigorous clinical validation and advanced manufacturing processes. Its primary therapeutic focus includes chronic prostatitis, benign prostatic hyperplasia (BPH), and prostate cancer. Medoncare's lead commercial product, Qianlieshutong, is a widely prescribed botanical treatment in China for prostate health. The company maintains a robust R&D pipeline featuring both novel small molecules and standardized botanical extracts. By combining traditional herbal knowledge with modern drug discovery platforms, Medoncare aims to provide effective and safe alternatives for chronic disease management.